Skip to content


Shining a light on the treatment of CNS disorders and cancer care.

SK Life Science is here listening to the needs of healthcare providers, patients, caregivers, advocates, and scientists. We are developing new molecules, enhancing advocacy efforts, and providing solutions that change what’s possible in the treatment of CNS disorders and cancer care.

Our Medicines

SK Life Science is committed to accelerating the development of next generation treatments for CNS disorders and cancer care. SK Biopharmaceuticals and SK Life Science independently developed XCOPRI® (cenobamate tablets) CV from inception through FDA approval.

For More Information

XCOPRI Website
XCOPRI Medication Guide
XCOPRI Prescribing Information
SK Life Science Navigator Program for Patient Access

The two companies also discovered and licensed-out the FDA and EMA-approved treatment for sleep disorders after completing phase 1 clinical trials.

For any medical information inquiries on our medicines, please visit

Global Patient Safety

Ensuring the safety of patients is our top priority.

We do this through pharmacovigilance monitoring. For more information, please see here.

Our Global Pipeline

SK Life Science and its parent company SK Biopharmaceuticals have 8 compounds under development globally.

Compound Indication
Phase 1
Phase 2
Phase 3
Focal (partial) – Onset Seizures1 (Asia)
Primary Generalized Tonic-Clonic Seizures
Lennox-Gastaut Syndrome
Rare Neuro­logical Disease
Advanced Solid Tumors
Attention Deficit / Hyper­activity Dis­order
Bipolar Disorder

* Partnership
1 In 2020, SK Biopharmaceuticals, the parent company of SK Life Science, initiated a clinical development program for cenobamate in China, Japan and Korea

Invigorating Next Generation Discovery

We are a group of scientists, inventors, and explorers tirelessly working to develop solutions that will improve CNS and cancer care

Leveraging Technologies to Include:

  • Target-based drug discovery techniques
  • High throughput organic screening (HTOs)/high content screening (HCS)
  • Computer-aided drug design (CADD)
  • Combinatorial chemistry

Key R&D Sectors:

We deploy our technologies in the areas of biology/discovery, medicinal chemistry, and pharmacology. The goal of research in these areas is to bring meaningful products to market.

Select A Sector For Details

We are responsible for lead compound discovery and optimization. This sector:

  • IDENTIFIES and validates signal and molecular targets
  • DEVELOPS screening technologies
  • PERFORMS high-throughput screening (HTS) leveraging technologies
  • PARTICIPATES in joint studies on targets known to have high target-disease correlation
  • INVESTIGATES the efficacy and safety of lead compounds

The medicinal chemistry sector of SK Life Science is responsible for:

  • IDENTIFYING a wide array of drug candidates for the treatment of CNS disorders and cancer
  • OPTIMIZING lead compounds in terms of their structure-activity relationships
  • DEVELOPING processes for clinical candidates to lead compound discovery and optimization

To maximize efficiency, we have implemented a CADD system, a high-efficiency synthesis infrastructure, an established structure-diverse library, and a target focus library.

The pharmacology sector is responsible for research programs in which drug candidates are studied to enable prediction of drug activity in the human body.

Grant Requests

Medical Education Grant Request

Please complete and return the Medical Education Grant Request form and the outlined documents to request a Medical Education Grant. Grant requestors will be notified within 30 days of submission. The documents listed in the form must be submitted to, along with a completed Medical Education Grant Request form.

Investigator Initiated Study Proposal Procedure

All requested information must be submitted to Decisions are made based on medical and scientific merit as well as available budget.

Following the Submission:

  • SK Life Science will acknowledge receipt of all Investigator Initiated Study (IIS) proposals via email.
  • The IIS Committee will review the request to determine SK Life Science initial interest in the proposal.
  • If the IIS Committee has interest in the proposal, the submitter will need to provide certain documents, including a full protocol, which will be reviewed by the IIS Committee.
  • A formal notification of the outcome of the review will be sent via email.

Expanded Access & Compassionate Use

Please click on the below button to learn more about SK Life Science’s Expanded Access and Compassionate Use policy.